08:00 Tue 22 Aug 2017
OptiBiotix Health - Global manufacturing & supply agreement with Sacco
("OptiBiotix" or "the Company")
Global manufacturing and supply agreement with Sacco S.r.l.
The agreement grants Sacco an exclusive licence to manufacture and supply OptiBiotix's cholesterol and blood pressure reducing LPLDL® strain in the US and ROW, in return for 50% of the profit, with a guaranteed cost of manufacture and minimum sales price per kilogramme to secure against discounting. The agreement brings the following benefits:-
1. Access to the US, the worlds largest probiotic market, with an estimated retail value of
2. Extension of LPLDL® into dairy applications utilising Sacco's network in the dairy industry to develop commercial opportunities identified by them in the global
3. Economies of scale, significantly reducing the manufacturing cost of LPLDL®, increasing OptiBiotix's profitability, and opening up new application opportunities
4. Long-term security of supply with Sacco's ability to produce at different locations from multiple facilities
5. A commitment from Sacco to support the funding of further developments of LPLDL®, including marketing and human studies, to expand the commercialisation of LPLDL® into new markets
This agreement is a strategic step to access the US probiotic supplement market, and to extend the opportunities offered by LPLDL® into dairy applications, with one of the largest and internationally respected supplier of probiotic ingredients. The US is one of the largest and fastest growing probiotic markets in the world, with supplements alone accounting for
Market data from 'TRENDS, INNOVATIONS AND OPPORTUNITIES DRIVING THE GLOBAL PROBIOTICS MARKET' (
For further information, please contact:
|
||||
|
Contact via Walbrook below |
|||
|
|
|||
|
Tel: 020 7213 0880 |
|||
|
|
|||
|
|
|||
finnCap (Broker) |
Tel: 020 7220 0500 |
|||
|
|
|||
Tony Quirke / |
|
|||
|
|
|||
|
Tel: 020 7933 8780 or optibiotix@walbrookpr.com |
|||
|
Mob: 07876 741 001 |
|||
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
About Sacco
Sacco, founded in 1934, is one of
This information is provided by RNS
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE